JCO global oncologyHumansMaleFemaleProspective StudiesDihydropyrimidine Dehydrogenase Deficiency
Clinical Implications of Dihydropyrimidine Dehydrogenase Deficiency in GI and Hepatopancreaticobiliary Cancers Treated With Fluoropyrimidines: A Prospective Observational Study.
Varun Goel, Dharmishtha Ashis Basu, Arpit Jain, Nivedita Patnaik, Akanksha Jaju, Anurag Mehta, Vineet Talwar
Published: 202510.1200/GO-25-00442
Abstract
PURPOSE: Dihydropyrimidine dehydrogenase (DPD) deficiency, an autosomal recessive metabolic disorder, causes a considerable deficit in the patient's metabolism of fluoropyrimidine drugs, most notably 5-fluorouracil (5-FU) and capecitabine. There is a…
Preview only. Read the full abstract at the source